DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Assetmark Inc.

Assetmark Inc. lowered its position in DexCom, Inc. (NASDAQ:DXCM) by 29.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 939 shares of the medical device company’s stock after selling 384 shares during the quarter. Assetmark Inc.’s holdings in DexCom were worth $64,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Golden State Wealth Management LLC lifted its holdings in DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after buying an additional 264 shares in the last quarter. Private Trust Co. NA lifted its holdings in DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company’s stock worth $46,000 after buying an additional 335 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in DexCom by 29.3% in the 1st quarter. Farther Finance Advisors LLC now owns 3,100 shares of the medical device company’s stock worth $209,000 after buying an additional 702 shares in the last quarter. Dynamic Advisor Solutions LLC lifted its holdings in DexCom by 34.2% in the 1st quarter. Dynamic Advisor Solutions LLC now owns 5,235 shares of the medical device company’s stock worth $357,000 after buying an additional 1,333 shares in the last quarter. Finally, Stonebridge Financial Group LLC lifted its holdings in DexCom by 944.5% in the 1st quarter. Stonebridge Financial Group LLC now owns 3,217 shares of the medical device company’s stock worth $220,000 after buying an additional 2,909 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on DXCM shares. Morgan Stanley boosted their price objective on shares of DexCom from $82.00 to $89.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 15th. Piper Sandler upped their target price on shares of DexCom from $90.00 to $100.00 and gave the company an “overweight” rating in a research note on Thursday, July 31st. UBS Group upped their target price on shares of DexCom from $105.00 to $106.00 and gave the company a “buy” rating in a research note on Thursday, July 31st. The Goldman Sachs Group assumed coverage on shares of DexCom in a research note on Friday, May 30th. They issued a “buy” rating and a $104.00 target price on the stock. Finally, Citigroup restated a “buy” rating and issued a $102.00 target price (up previously from $82.00) on shares of DexCom in a research note on Thursday, May 22nd. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $99.89.

Insider Activity at DexCom

In other news, EVP Sadie Stern sold 6,184 shares of the stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $85.11, for a total value of $526,320.24. Following the completion of the transaction, the executive vice president directly owned 109,621 shares in the company, valued at $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Nicholas Augustinos sold 3,672 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $304,041.60. Following the sale, the director owned 33,411 shares of the company’s stock, valued at $2,766,430.80. The trade was a 9.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,656 shares of company stock valued at $2,412,191. Insiders own 0.32% of the company’s stock.

DexCom Price Performance

Shares of NASDAQ:DXCM opened at $76.25 on Tuesday. The firm’s 50 day moving average is $84.40 and its two-hundred day moving average is $80.54. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25. The firm has a market capitalization of $29.90 billion, a P/E ratio of 52.95, a PEG ratio of 1.66 and a beta of 1.43. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom’s revenue was up 15.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.43 earnings per share. Analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.